The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review.
about
Recent advances in the genetics of systemic sclerosis: toward biological and clinical significanceSurvival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertensionTherapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis.Management of Widespread Skin Thickening in Diffuse Systemic Sclerosis.Cardiovascular magnetic resonance patterns of biopsy proven cardiac involvement in systemic sclerosis.Sex differential association of dermatomyositis with Sjögren syndrome.Diagnosis and Management of Systemic Sclerosis: A Practical Approach.Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).Fibrosing myopathy in systemic sclerosis associates with higher mortality.Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension.Scleroderma renal crisis and renal involvement in systemic sclerosis.Emerging drugs and therapeutics for systemic sclerosis.Geographic variation as a risk factor for digital ulcers in systemic sclerosis patients: a multicentre registry.Independent Association of Severity of Muscle Weakness With Disability as Measured by the Health Assessment Questionnaire Disability Index in Scleroderma.Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis.Intestinal pseudo-obstruction in patients with systemic sclerosis: an analysis of the Nationwide Inpatient Sample.Pulmonary arterial hypertension in scleroderma: care gaps in screeningSafety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).Connective tissue diseases: To screen or not to screen for PAH in connective tissue diseases?Points to consider in renal involvement in systemic sclerosis.Muscle involvement in systemic sclerosis: points to consider in clinical trials.Points to consider when doing a trial primarily involving the heart.Trial methodology in scleroderma: Avoiding a shot in the dark.End-Stage Kidney Disease From Scleroderma in the United States, 1996 to 2012.Right ventricular and atrial functions in systemic sclerosis patients without pulmonary hypertension. Speckle-tracking echocardiographic study.Contribution of CD8+ T cells to inflammatory cytokine production in systemic sclerosis (SSc).Immune-Mediated Heart Disease.Could nailfold videocapillaroscopy usher in a new era of preventative disease-modifying therapeutic intervention in systemic sclerosis?
P2860
Q28088499-E50B425C-4A3A-4F94-BC5A-8E6D4AA9734DQ33759804-52B359CF-569B-4107-93EA-81E42AE21330Q36709262-0B8FA920-4E4A-44B0-BB33-981D805B245EQ37003312-896AAC1A-C460-4D09-AC1F-F9BB704BE933Q37355752-B00DAB3E-7F3B-43B1-AD24-5B8727F2D345Q37621925-2EA39DB4-044D-4177-9ACE-78A96C3F757FQ38667111-FC7E2876-A156-4476-B512-2246F15C776CQ38721897-AE30D45D-C225-4342-BBEF-DAD99CE63447Q38763676-5CB9863A-33F9-4DC6-8877-93B7280078E8Q38914965-D7AF9D00-3C15-4A99-AA11-7716A13D2F7EQ38957950-A756D96A-FEFD-4AA3-8D50-BC234A3078A7Q38998611-E9045C42-DE2F-45C5-B718-F77EE0A1CEECQ39084290-90EF0B85-450E-4DFC-A532-EB40FC34F5D5Q39993595-428778C2-04DD-472E-86E0-5CA4279376D4Q40210480-0DD78A56-EA83-4F0E-B005-D2451E0F85E7Q40266041-0FB98993-AF5F-47EE-98A0-A63D07D6B142Q42341604-F02A5485-8A48-45A2-A9C3-79F8AD812DDCQ42698900-CD75EA3F-5054-4671-A22C-F74D089D3087Q44273441-030DD7A9-E7BE-4391-965A-C91FD29CFBE1Q45995241-2DCFA8A8-F7D7-49FF-A50B-10C0032E7810Q46256178-970C1B4A-6D0C-4E35-AAD1-A254ED3D4CE4Q47835792-70906F2F-EA60-4461-A9D5-97F09F2B897AQ49384975-8DF89793-F31C-476D-A151-EBCA1666FF5DQ49594527-8697A950-0C7C-4FB8-B698-249748D6452DQ50615614-CDA87F60-39E5-44FC-AAC1-AB6DB1F6B4C0Q50628688-3A214541-87F0-4A10-A20A-22621BB6CF91Q51835838-7AA9B011-A9A4-4CBC-A43A-047BFE76AC89Q53600592-70C7B1A9-6FF7-4B61-A37F-71DC26B4B334
P2860
The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The 15% rule in scleroderma: t ...... clerosis. A systematic review.
@en
type
label
The 15% rule in scleroderma: t ...... clerosis. A systematic review.
@en
prefLabel
The 15% rule in scleroderma: t ...... clerosis. A systematic review.
@en
P2093
P356
P1476
The 15% rule in scleroderma: t ...... clerosis. A systematic review.
@en
P2093
Canadian Scleroderma Research Group
Chayawee Muangchan
Janet Pope
Murray Baron
P304
P356
10.3899/JRHEUM.121380
P407
P577
2013-07-15T00:00:00Z